Daphne W Bell

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Our changing view of the genomic landscape of cancer
    Daphne W Bell
    National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Pathol 220:231-43. 2010
  2. pmc Predisposition to cancer caused by genetic and functional defects of mammalian Atad5
    Daphne W Bell
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Genet 7:e1002245. 2011
  3. pmc Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts
    Daphne W Bell
    Massachusetts General Hospital Cancer Center, Charlestown, MA, USA
    Int J Cancer 121:2661-7. 2007
  4. pmc Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin
    Jianmin Zhang
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Mol Cancer Res 7:1510-6. 2009
  5. pmc Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
    Nadia Godin-Heymann
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Res 67:7319-26. 2007
  6. pmc Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
    Gromoslaw A Smolen
    Cancer Center and Department of Pathology, Molecular Pathology Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 103:2316-21. 2006
  7. ncbi request reprint Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 25:587-95. 2007
  8. ncbi request reprint Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA
    J Clin Oncol 23:8081-92. 2005
  9. ncbi request reprint Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Daphne W Bell
    Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Genet 37:1315-6. 2005
  10. pmc Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 14:4079-84. 2008

Collaborators

Detail Information

Publications29

  1. pmc Our changing view of the genomic landscape of cancer
    Daphne W Bell
    National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Pathol 220:231-43. 2010
    ....
  2. pmc Predisposition to cancer caused by genetic and functional defects of mammalian Atad5
    Daphne W Bell
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Genet 7:e1002245. 2011
    ..Taken together, our findings indicate that loss-of-function mutations in mammalian Atad5 are sufficient to cause genomic instability and tumorigenesis...
  3. pmc Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts
    Daphne W Bell
    Massachusetts General Hospital Cancer Center, Charlestown, MA, USA
    Int J Cancer 121:2661-7. 2007
    ....
  4. pmc Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin
    Jianmin Zhang
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Mol Cancer Res 7:1510-6. 2009
    ....
  5. pmc Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
    Nadia Godin-Heymann
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Res 67:7319-26. 2007
    ....
  6. pmc Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
    Gromoslaw A Smolen
    Cancer Center and Department of Pathology, Molecular Pathology Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 103:2316-21. 2006
    ..MET amplification may thus identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway and define a patient group that is appropriate for clinical trials of targeted therapy using MET inhibitors...
  7. ncbi request reprint Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 25:587-95. 2007
    ....
  8. ncbi request reprint Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA
    J Clin Oncol 23:8081-92. 2005
    ..The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib...
  9. ncbi request reprint Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
    Daphne W Bell
    Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Genet 37:1315-6. 2005
    ..Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer...
  10. pmc Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 14:4079-84. 2008
    ....
  11. ncbi request reprint Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 12:4283-7. 2006
    ..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers...
  12. pmc Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    Eunice L Kwak
    Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 102:7665-70. 2005
    ..Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib...
  13. ncbi request reprint Epidermal growth factor receptor mutations in lung cancer
    Sreenath V Sharma
    Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Rev Cancer 7:169-81. 2007
    ....
  14. ncbi request reprint Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib
    Roseann Mulloy
    Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA
    Cancer Res 67:2325-30. 2007
    ....
  15. pmc A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas
    Meghan L Rudd
    Cancer Genetics Branch, National Human Genome Research Institute, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 17:1331-40. 2011
    ..The goal of this study was to comprehensively define the incidence of mutations in all exons of PIK3CA in both endometrioid endometrial cancer (EEC) and nonendometrioid endometrial cancer (NEEC)...
  16. ncbi request reprint Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis
    Gromoslaw A Smolen
    Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, MA 02129, USA
    Cancer Res 66:3452-5. 2006
    ....
  17. pmc Detection of mutations in EGFR in circulating lung-cancer cells
    Shyamala Maheswaran
    Massachusetts General Hospital Cancer Center, Boston 02129, USA
    N Engl J Med 359:366-77. 2008
    ..Molecular characterization of circulating tumor cells may provide a strategy for noninvasive serial monitoring of tumor genotypes during treatment...
  18. ncbi request reprint Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Building 149, CNY 7, 13th Street, Charlestown, MA 02129, USA
    Gynecol Oncol 98:124-8. 2005
    ..We have previously reported somatic mutations in AGO in 3/10 ovarian cancer cell lines, but the frequency of such mutations in primary ovarian cancer is unknown...
  19. pmc A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway
    Myoung Shin Kim
    Genetics of Development and Disease Branch, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 285:14585-93. 2010
    ..Taken together, our results demonstrate that the WT1 negatively regulates WNT/beta-catenin pathway via its target gene WID and further suggest a role for WID in nephrogenesis...
  20. pmc Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias
    Woo Jae Kim
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Blood 111:4716-22. 2008
    ..Taken together, these observations suggest that disruption of the ceramide pathway may contribute to a subset of human leukemias...
  21. ncbi request reprint salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines
    Nicolas Tapon
    Massachusetts General Hospital Cancer Center, Building 149, 13th Street, Charlestown 02129, USA
    Cell 110:467-78. 2002
    ..The human ortholog of salvador (hWW45) is mutated in three cancer cell lines. Thus, salvador restricts cell numbers in vivo by functioning as a dual regulator of cell proliferation and apoptosis...
  22. pmc Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes
    Matthieu Le Gallo
    Cancer Genetics Branch, National Human Genome Research Institute, US National Institutes of Health NIH, Bethesda, MD, USA
    Nat Genet 44:1310-5. 2012
    ....
  23. ncbi request reprint DOCK4, a GTPase activator, is disrupted during tumorigenesis
    Vijay Yajnik
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Cell 112:673-84. 2003
    ..DOCK4 therefore encodes a CDM family member that regulates intercellular junctions and is disrupted during tumorigenesis...
  24. ncbi request reprint Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein
    Jingyung Hur
    Department of Tumor Biology, Massachusetts General Hospital Center for Cancer Research, Charlestown, Massachusetts 02129, USA
    Cancer Res 66:10153-61. 2006
    ..These results suggest that expression of BIK in human breast cancer cells is regulated at the mRNA level by a mechanism involving a nontranscriptional activity of p53 and by proteasomal degradation of BIK protein...
  25. ncbi request reprint An X chromosome gene, WTX, is commonly inactivated in Wilms tumor
    Miguel N Rivera
    Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA 02114, USA
    Science 315:642-5. 2007
    ..In contrast to biallelic inactivation of autosomal tumor-suppressor genes, WTX is inactivated by a monoallelic "single-hit" event targeting the single X chromosome in tumors from males and the active X chromosome in tumors from females...
  26. pmc PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer
    Mary E Urick
    Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 71:4061-7. 2011
    ....
  27. ncbi request reprint Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
    Raffaella Sordella
    Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Building 149, 13th Street, Charlestown, MA 02129, USA
    Science 305:1163-7. 2004
    ..Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy...
  28. pmc Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A
    Jessica C Price
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e63313. 2013
    ..Our findings warrant future studies to determine whether these mutations are driver events that contribute to the pathogenesis of endometrial cancer...
  29. ncbi request reprint Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2
    Daphne W Bell
    Center for Cancer Risk Analysis, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Cancer Res 62:2741-3. 2002
    ..The distinct histopathological features of these tumors may reflect the acquisition of subsequent genetic events...